Costimulation of T cells for tumor immunity

doi:10.1016/0167-5699(93)90262-J

Immunology Today

Volume 14, Issue 10, October 1993, Pages 483-486

Immunology Today

https://doi.org/10.1016/0167-5699(93)90262-J Get rights and content

Abstract

Tumor specific antigens can be demonstrated on many neoplasms by immunization and challenge experiments; however, these antigens do not normally elicit a sufficiently strong immune response to prevent tumor growth in immunocompetent hosts. Recent studies have demonstrated that efficient activation of T cells requires costimulation of the CD28 receptor via the B7 molecule on antigen-presenting cells. Inadequate costimulation of tumor-reactive T cells may contribute to the fact that antigenic tumors are not normally rejected by the immune system, and weak anti-tumor immune responses may be amplified by upregulation of CD28 triggering.

References (24)

K.E. Hellström et al.
Adv. Cancer Res.
(1969)
C.J. Melief
Adv. Cancer Res.
(1992)
P.D. Greenberg
Adv. Immunol.
(1991)
J.W. Yewdell et al.
Adv. Immunol.
(1992)
J.M. Bishop
Cell
(1991)
Y. Liu et al.
Curr. Opin. Immunol.
(1992)
L. Chen et al.
Cell
(1992)
R.H. Schwartz
Cell
(1992)
K.E. Hellström et al.
A.J. Levine et al.
Nature
(1991)

H. zur Hausen

Science

(1991)

L. Chen et al.

Cited by (345)

CAR-T cells: Early successes in blood cancer and challenges in solid tumors
2021, Acta Pharmaceutica Sinica B
New approaches to cancer immunotherapy have been developed, showing the ability to harness the immune system to treat and eliminate cancer. For many solid tumors, therapy with checkpoint inhibitors has shown promise. For hematologic malignancies, adoptive and engineered cell therapies are being widely developed, using cells such as T lymphocytes, as well as natural killer (NK) cells, dendritic cells, and potentially others. Among these adoptive cell therapies, the most active and advanced therapy involves chimeric antigen receptor (CAR)-T cells, which are T cells in which a chimeric antigen receptor is used to redirect specificity and allow T cell recognition, activation and killing of cancers, such as leukemia and lymphoma. Two autologous CAR-T products have been approved by several health authorities, starting with the U.S. Food and Drug Administration (FDA) in 2017. These products have shown powerful, inducing, long-lasting effects against B cell cancers in many cases. In distinction to the results seen in hematologic malignancies, the field of using CAR-T products against solid tumors is in its infancy. Targeting solid tumors and trafficking CAR-T cells into an immunosuppressive microenvironment are both significant challenges. The goal of this review is to summarize some of the most recent aspects of CAR-T cell design and manufacturing that have led to successes in hematological malignancies, allowing the reader to appreciate the barriers that must be overcome to extend CAR-T therapies to solid tumors successfully.
Review of immune checkpoint inhibitors in immuno-oncology
2021, Advances in Pharmacology
Citation Excerpt :
The binding of the MHC:peptide complex to a TCR is the first step in activating a naive T cell. To be fully functional the T cell requires a second signal (Fig. 1) (Chen, Linsley, & Hellstrom, 1993; Hellstrom, Hellstrom, Linsley, & Chen, 1993). The interaction between CD28 on a T cell with CD80 and CD86 on an APC is termed the “co-stimulatory” pathway.
Tumor cells predominantly express self-antigens and overcoming self-tolerance is the primary challenge to effective immunotherapy. Tumors also express ligands for co-inhibitory molecules on immune cells, in order to suppress anti-tumor immunity. Over a decade ago, the first antibodies generated to block the co-inhibitory molecule CTLA-4 was tested in patients with metastatic melanoma. Results from this landmark trial have informed not only the current landscape of checkpoint blockade but also the way in which immunotherapy trial outcomes are determined. Antibodies targeting PD-1 and its ligand, PD-L1, soon followed and use of these checkpoint inhibitors (ICIs) have expanded exponentially. ICI treatment has shown long-lasting clinical benefit in several tumor types and patients refractory to other treatments can often respond to ICI therapy. On the other hand, in some tumor types, the response to ICI is short-lived and tumors eventually recur. Current clinical trials are focused on enhancing anti-tumor effects through combinations of multiple ICIs with agents which cause tumor death, particularly in solid tumors, in order to enhance antigen presentation. It is also important to define which patients will respond to therapy with ICIs as over half of all patients suffer from immune-related adverse events (irAE), some of which are severe and long-lasting.
Autoantibodies as diagnostic and prognostic cancer biomarker: Detection techniques and approaches
2019, Biosensors and Bioelectronics
Citation Excerpt :
Melanoma antigens are usually expressed in the male testicular cells. Additional mechanisms associated with autoantibodies inhibitions are i) downregulation of antigen presenting cell, MHC class I molecules (Hofbauer et al., 2005) ii) lack of expression of co-stimulatory molecules on the tumor cells (Chen et al., 1993) iii) tumors producing immunosuppressive factors like TGF-, IL-10 and VEGF (Kusmartsev and Gabrilovich, 2006). The immunogenicity of a tumor depends on several factors that may be variable even among tumors of a similar type.
Autoantibodies produced by the patients’ own immune systems in response to foreign substances are emerging as an attractive biomarker for early detection of cancer. These serum immunobiomarkers are produced in large quantities despite the presence of very less amount of the corresponding antigens, and thus presenting themselves as a novel class of stable and minimally invasive disease biomarkers especially for cancer diagnosis. Although a plethora of research, including conventional molecular biology-based as well as cutting-edge optical and electrochemical strategies (biosensor), have been conducted to detect autoantibodies, most of these strategies are yet to be readily applicable in the off-laboratory settings at clinics. Herein, we detail the biogenesis, diagnostic, prognostic and therapeutic potential of autoantibodies as cancer biomarkers. With the particular emphasis on cutting-edge advances in electrochemistry, optical (surface plasmon resonance) and microfluidics techniques, this review entrusts the unmet needs and challenges of autoantibody detection approaches and provides a future perspective of the presented strategies. We believe this review can potentially guide the researchers towards the development of robust, reliable and sensitive detection strategies for tumor-associated autoantibodies and translation of these biomarkers to real clinical settings for diagnosis and prognosis of cancer.
Critical role of transcription factor PU.1 in the expression of CD80 and CD86 on dendritic cells
2011, Blood
Citation Excerpt :
In the present study, we succeeded in both the suppression and induction of CD80 and CD86 expression by targeting a single transcription factor. One crucial role of CD80 and CD86 is the costimulation of the T-cell response and the induction of T cell–mediated immunity, such as the rejection of tumors.52,53 Conversely, their other crucial role is to block the development of several autoimmune diseases or to induce donor-specific tolerance to allografts by abrogation of CD28/B7 signals.47-50
In this study, we investigated the role of a transcription factor, PU.1, in the regulation of CD80 and CD86 expression in dendritic cells (DCs). A chromatin immunoprecipitation assay revealed that PU.1 is constitutively bound to the CD80 and CD86 promoters in bone marrow–derived DCs. In addition, co-expression of PU.1 resulted in the transactivation of the CD80 and CD86 promoters in a reporter assay. The binding of PU.1 to cis-enhancing regions was confirmed by electromobility gel-shift assay. As expected, inhibition of PU.1 expression by short interfering RNA (siRNA) in bone marrow–derived DCs resulted in marked down-regulation of CD80 and CD86 expression. Moreover, overexpression of PU.1 in murine bone marrow–derived lineage-negative cells induced the expression of CD80 and CD86 in the absence of monocyte/DC-related growth factors and/or cytokines. Based on these results, we conclude that PU.1 is a critical factor for the expression of CD80 and CD86. We also found that subcutaneous injection of PU.1 siRNA or topical application of a cream-emulsified PU.1 siRNA efficiently inhibited murine contact hypersensitivity. Our results suggest that PU.1 is a potential target for the treatment of immune-related diseases.
Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-α and interferon-α
2009, Journal of Dermatological Science
Citation Excerpt :
TNF-α dependent inhibition of neutral red uptake of 4 × 104 U937 cells/well was studied in the absence of blocking Abs and in the presence of commercial anti-TNF-α Abs (TNF-alpha/TNFSF1A, R&D), and Abs purified from the three psoriatic patients (1 μg/ml of each Ab). Since the levels of IFN-α correlate with increased inhibition of T-cell growth, the ability of anti-IFN-α auto Abs purified from three psoriatic patients with high titers to prevent IFN-α induced inhibition of normal T-cells proliferation was examined [16]. Anti-CD3ɛ mAb (BD Biosciences) was immobilized to a 96-well plate (2 μg/ml, 50 μl/well) for 1 h at 37 °C.
It has been shown in experimental animal models that were extended to humans that during autoimmune conditions, the immune system generates beneficial autoantibody (auto Ab) response to a limited number of inflammatory mediators that drive the pathogenesis of the disease.
To investigate the presence of auto Abs to cytokines and chemokines in psoriasis.
Sera were obtained from patients with psoriasis (n = 37), atopic dermatitis (AD) (n = 18) and healthy volunteers (n = 56). The titers of auto (Abs) to TNF-α, interferon-α (IFN-α), interleukin-17 (IL-17), and chemokines CCL2, CCL3 and CCL5 were determined using enzyme-linked immunosorbant assay. Neutralizing activities of high-titer auto Abs to TNF-α and IFN-α were determined using functional in vitro assays.
Highly significant increased titers of auto Abs to TNF-α and IFN-α were detected in patients with psoriasis compared with healthy subjects and patients with AD (mean titers more than fourfold). These auto Abs demonstrated some neutralizing activity in vitro, but their serum levels did not correlate with the intensity and duration of the disease and with phototherapy induced remissions. Significantly increased titers albeit to a lesser extent, of auto Abs to CCL3 were detected in AD.
Psoriasis patients produce markedly increased levels of auto Abs to TNF-α and IFN-α which are two of the key cytokines in this disorder. The presence of these auto Abs which possess some neutralizing activity in vitro, may be an epiphenomenon or might play a role in attempting to suppress the ongoing inflammatory process.
Clinicopathologic Evaluation of CD80, CD86, and PD-L1 Expressions with Immunohistochemical Methods in Malignant Melanoma Patients
2024, Turk Patoloji Dergisi

View all citing articles on Scopus

View full text

viewpointCostimulation of T cells for tumor immunity

Abstract

Adv. Cancer Res.

Adv. Cancer Res.

Adv. Immunol.

Adv. Immunol.

Cell

Curr. Opin. Immunol.

Cell

Cell

Nature

Science

viewpoint
Costimulation of T cells for tumor immunity